Italy - English - HMA (Heads of Medicines Agencies)

sogeval - enrofloxacin 15 mg - tablet - dogs young - enrofloxacin

Netherlands - English - HMA (Heads of Medicines Agencies)

sogeval - enrofloxacin 15 mg - tablet - dogs young - enrofloxacin

Portugal - English - HMA (Heads of Medicines Agencies)

sogeval - enrofloxacin 15 mg - tablet - dogs young - enrofloxacin

Romania - English - HMA (Heads of Medicines Agencies)

sogeval - enrofloxacin 15 mg - tablet - dogs young - enrofloxacin

United Kingdom - English - HMA (Heads of Medicines Agencies)

sogeval - enrofloxacin 15 mg - tablet - dogs young - enrofloxacin

Ireland - English - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - enrofloxacin - tablets - 150 mg/tablet - enrofloxacin - canine - antibacterial

Ireland - English - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - enrofloxacin - tablets - 50 mg/tablet - enrofloxacin - canine - antibacterial

United States - English - NLM (National Library of Medicine)

novartis animal health us, inc. - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - enrofloxacin 22.7 mg

United States - English - NLM (National Library of Medicine)

norbrook laboratories limited - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - enrofloxacin 22.7 mg in 1 ml - enroflox® (brand of enrofloxacin) injectable solution is indicated for the management of diseases in dogs associated with bacteria susceptible to enrofloxacin. enrofloxacin is contraindicated in dogs known to be hypersensitive to quinolones. based on the studies discussed under the section on animal safety summary, the use of enrofloxacin is contraindicated in small and medium breeds of dogs during the rapid growth phase (between 2 and 8 months of age). the safe use of enrofloxacin has not been established in large and giant breeds during the rapid growth phase. large breeds may be in this phase for up to one year of age and the giant breeds for up to 18 months. in clinical field trials utilizing a daily oral dose of 5.0 mg/kg, there were no reports of lameness or joint problems in any breed. however, controlled studies with histological examination of the articular cartilage have not been conducted in the large or giant breeds.

United States - English - NLM (National Library of Medicine)

mwi/vetone - enrofloxacin (unii: 3dx3xek1bn) (enrofloxacin - unii:3dx3xek1bn) - enrofloxacin 22.7 mg in 1 ml - enrosite™ (brand of enrofloxacin) injectable solution is indicated for the management of diseases in dogs associated with bacteria susceptible to enrofloxacin. enrofloxacin is contraindicated in dogs known to be hypersensitive to quinolones. based on the studies discussed under the section on animal safety summary, the use of enrofloxacin is contraindicated in small and medium breeds of dogs during the rapid growth phase (between 2 and 8 months of age). the safe use of enrofloxacin has not been established in large and giant breeds during the rapid growth phase. large breeds may be in this phase for up to one year of age and the giant breeds for up to 18 months. in clinical field trials utilizing a daily oral dose of 5.0 mg/kg, there were no reports of lameness or joint problems in any breed. however, controlled studies with histological examination of the articular cartilage have not been conducted in the large or giant breeds.